Last Price$175.8(3.8%)
Market Cap$14.5B
LTM Research & Development Expenses (R&D)
$0.0
YoY Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
Stock quality & Intrinsic value
6/10
87.3% undervalued
ICON Public Limited Company Research & Development Expenses (R&D)
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Expenses (R&D) | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Overvalued or undervalued?
Check the intrinsic value for ICLR
and see if it's the right time to invest.
ICON Public Limited Company (ICLR) Research & Development Expenses (R&D) comparison analysis
General
LTM Research & Development Expenses (R&D)
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
ICON Public Limited CompanyICLR
$0.0
N/A
N/A
N/A
Median Peer Set
$208.3M
3.1%
0.3%
5.0%
Danaher CorporationDHR
$1,584.0M
5.4%
(3.1%)
4.9%
Thermo Fisher Scientific Inc.TMO
$1,390.0M
4.0%
(0.4%)
6.7%
Agilent Technologies, Inc.A
$464.0M
(2.9%)
0.7%
2.7%
Natera, Inc.NTRA
$404.1M
26.0%
15.2%
51.1%
IDEXX Laboratories, Inc.IDXX
$219.8M
15.1%
10.9%
10.5%
Revvity, Inc.RVTY
$196.8M
(9.1%)
(10.5%)
0.8%
Mettler-Toledo International Inc.MTD
$189.4M
2.2%
3.7%
5.6%
Waters CorporationWAT
$183.0M
4.6%
2.8%
5.1%
IQVIA Holdings Inc.IQV
$0.0
N/A
N/A
N/A
Quest Diagnostics IncorporatedDGX
$0.0
N/A
N/A
N/A
ICLR key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 0.0 (100.0%) | 455.6 0.0% | 630.7 38.4% | 865.2 37.2% | 887.6 2.6% | 900.0 1.4% | 945.7 5.1% | 1,115.0 17.9% | 1,336.1 19.8% | 1,503.3 12.5% | 1,575.0 4.8% | 1,666.5 5.8% | 1,758.4 5.5% | 2,595.8 47.6% | 2,805.8 8.1% | 2,797.3 (0.3%) | 5,480.8 95.9% | 7,741.4 41.2% | 8,120.2 4.9% | 8,281.7 2.0% |
| Cost of Goods Sold (COGS) | 0.0 | 256.3 | 354.5 | 489.2 | 507.8 | 541.4 | 611.9 | 718.1 | 845.4 | 903.2 | 909.0 | 961.3 | 1,031.5 | 1,826.3 | 1,974.1 | 1,989.3 | 3,972.6 | 5,527.0 | 5,719.9 | 5,845.3 |
% margin | 0.0 0.0% | 199.3 43.8% | 276.2 43.8% | 376.0 43.5% | 379.8 42.8% | 358.7 39.8% | 333.8 35.3% | 396.9 35.6% | 490.6 36.7% | 600.1 39.9% | 666.0 42.3% | 705.2 42.3% | 727.0 41.3% | 769.5 29.6% | 831.7 29.6% | 808.0 28.9% | 1,508.2 27.5% | 2,214.3 28.6% | 2,400.2 29.6% | 2,436.4 29.4% |
| Operating Expenses | 0.0 | 151.5 | 207.0 | 276.5 | 272.4 | 266.6 | 294.5 | 327.3 | 360.4 | 389.0 | 384.5 | 385.3 | 395.0 | 392.4 | 398.3 | 416.1 | 900.3 | 1,348.3 | 1,444.1 | 1,338.5 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 0.0 | 136.6 | 188.0 | 248.8 | 230.9 | 232.7 | 255.9 | 280.8 | 313.9 | 336.5 | 326.8 | 325.7 | 323.7 | 325.8 | 336.7 | 341.7 | 585.3 | 778.8 | 776.4 | 728.3 |
% margin | 0.0 0.0% | 47.8 10.5% | 69.2 11.0% | 99.5 11.5% | 107.5 12.1% | 92.1 10.2% | 29.4 3.1% | 69.6 6.2% | 121.2 9.1% | 202.4 13.5% | 281.5 17.9% | 311.7 18.7% | 331.9 18.9% | 377.1 14.5% | 433.4 15.4% | 392.0 14.0% | 608.5 11.1% | 795.2 10.3% | 956.2 11.8% | 1,097.8 13.3% |
| Interest Income | 0.0 | 0.0 | 0.0 | 2.9 | 0.8 | 1.8 | 1.2 | 1.2 | 1.0 | 1.2 | 1.3 | 1.5 | 2.3 | 4.8 | 6.9 | 2.7 | 0.6 | 2.3 | 5.0 | 8.6 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 4.1 | 3.5 | 1.1 | 1.6 | 2.0 | 1.3 | 0.8 | 4.0 | 13.0 | 13.0 | 13.6 | 6.4 | 15.1 | 182.4 | 229.7 | 336.7 | 237.2 |
| Pre-tax Income | 0.0 | 51.5 | 72.0 | 98.3 | 104.7 | 92.7 | 29.0 | 68.7 | 120.9 | 202.7 | 278.9 | 300.2 | 327.7 | 368.4 | 427.0 | 382.2 | 196.7 | 567.9 | 624.5 | 869.2 |
% effective tax rate | 0.0 0.0% | 12.9 25.1% | 15.8 22.0% | 20.0 20.3% | 10.4 9.9% | 5.7 6.1% | 6.1 21.1% | 10.4 15.1% | 18.1 14.9% | 30.2 14.9% | 39.3 14.1% | 38.0 12.7% | 54.7 16.7% | 45.6 12.4% | 51.1 12.0% | 50.8 13.3% | 41.3 21.0% | 59.4 10.5% | 11.7 1.9% | 77.7 8.9% |
% margin | 0.0 0.0% | 38.3 8.4% | 56.0 8.9% | 78.1 9.0% | 94.3 10.6% | 87.1 9.7% | 22.9 2.4% | 58.3 5.2% | 102.8 7.7% | 172.5 11.5% | 239.5 15.2% | 262.2 15.7% | 272.9 15.5% | 322.8 12.4% | 374.0 13.3% | 327.8 11.7% | 153.2 2.8% | 505.3 6.5% | 612.3 7.5% | 791.5 9.6% |
| EPS | 0.00 | 1.35 | 1.95 | 1.34 | 1.61 | 1.46 | 0.38 | 0.97 | 1.69 | 2.80 | 4.08 | 4.75 | 5.04 | 5.96 | 6.94 | 6.29 | 2.28 | 6.20 | 7.46 | 9.60 |
| Diluted EPS | 0.00 | 1.33 | 1.88 | 1.30 | 1.57 | 1.44 | 0.37 | 0.96 | 1.65 | 2.73 | 3.97 | 4.65 | 4.98 | 5.90 | 6.88 | 6.24 | 2.25 | 6.13 | 7.40 | 9.53 |
% margin | 0.0 0.0% | 62.8 13.8% | 88.3 14.0% | 130.1 15.0% | 140.9 15.9% | 127.7 14.2% | 69.3 7.3% | 111.1 10.0% | 168.7 12.6% | 263.7 17.5% | 339.2 21.5% | 379.4 22.8% | 401.9 22.9% | 451.8 17.4% | 532.2 19.0% | 488.8 17.5% | 739.4 13.5% | 1,412.3 18.2% | 1,521.4 18.7% | 1,594.9 19.3% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is ICON Public Limited Company's Research & Development Expenses (R&D)?
As of today, ICON Public Limited Company's last 12-month Research & Development Expenses (R&D) is $0.0, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is ICON Public Limited Company's Research & Development Expenses (R&D) growth rate?
Over the last year, ICON Public Limited Company's Research & Development Expenses (R&D) growth was N/A. The average annual Research & Development Expenses (R&D) growth rates for ICON Public Limited Company have been N/A over the past three years, N/A over the past five years.